IFG
ARQT icon

Independent Financial Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Independent Financial Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,906
Closed -$210K – 1556
2026
Q1 		$210K Sell
8,906
-7,552
-46% -$193K ﹤0.01% 1352
2025
Q4 		$478K Buy
+16,458
New +$421K 0.01% 924

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Independent Financial Group's ARQT Position: Q2 2026 in Review

Independent Financial Group sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 8,906 shares — an estimated $210K sold.

Independent Financial Group first reported a position in ARQT in Q4 2025 and held it in 2 quarters. The position peaked at $478K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Independent Financial Group reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Independent Financial Group sold 8,906 Arcutis Biotherapeutics shares in Q2 2026, an estimated $210K.
  • Independent Financial Group first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Independent Financial Group's Arcutis Biotherapeutics position peaked at $478K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Independent Financial Group's 13F filing for Q2 2026, filed 15 Jul 2026.